var data={"title":"Pneumococcal conjugate vaccine (13-valent): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pneumococcal conjugate vaccine (13-valent): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/413330?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pneumococcal-conjugate-vaccine-13-valent-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pneumococcal conjugate vaccine (13-valent): Pediatric drug information \t&quot;</a> and <a href=\"topic.htm?path=pneumococcal-conjugate-vaccine-13-valent-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pneumococcal conjugate vaccine (13-valent): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9926715\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Prevnar 13</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11575096\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Prevnar 13</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10010046\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Bacterial)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10010070\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immunization: </b>IM: 0.5 mL as a single dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative recommendations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults 19 to &lt;65 years with specified underlying medical conditions: IM: 0.5 mL as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Which vaccines are indicated (pneumococcal conjugate vaccine [PCV 13] and/or pneumococcal polysaccharide vaccine [PPSV23]) is dependent on previous pneumococcal vaccination history; some medical conditions do not require PCV13 [see guidelines for details] (ACIP [Kim 2017]; ACIP [Kobayashi 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Pneumococcal vaccine-naive or vaccination status unknown:</i> Administer PCV13 followed by PPSV23 at least 8 weeks later</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Previously received PPSV23 but not PCV13:</i> Administer PCV13 &ge;1 year after the PPSV23 dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Previously received PCV13 but not PPSV23:</i> No additional PCV 13 doses are needed</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Revaccination:</i> Administration of additional doses is not recommended for adults (ACIP [Kim 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &ge;65 years: IM: 0.5 mL as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> All patients should receive both pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23) (ACIP [Kobayashi 2015]; CDC/ACIP [Tomczyk 2014]):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Pneumococcal vaccine-naive or vaccination status unknown:</i> Administer PCV13 followed by PPSV23 &ge;1 year later (minimum interval of 8 weeks for certain high-risk groups)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Previously received PPSV23 (at age &ge;65 years) but not PCV13:</i> Administer PCV13 &ge;1 year after the last dose of PPSV23</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Previously received PPSV23 (at age &lt;65 years) but not PCV13: </i>Administer PCV13 &ge;1 year after the last dose of PPSV23; administer PPSV23 &ge;1 year later (minimum interval of 8 weeks for certain high-risk groups) and at least 5 years after the last PPSV23 dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i> Previously received PCV13: </i> No additional PCV13 doses are needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hematopoietic stem cell transplantation (HSCT) (off-label):</b> IM: 0.5 mL for a total of 3 doses with first dose administered 3 to 6 months after HSCT followed by second and third doses administered at least 1 month apart (ACIP [Kroger 2017])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10010068\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=pneumococcal-conjugate-vaccine-13-valent-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pneumococcal conjugate vaccine (13-valent): Pediatric drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary immunization:</b> Infants and Children 6 weeks to 15 months: IM: 0.5 mL/dose for a total of 4 doses. The first dose may be given as young as 6 weeks of age, but is typically given at 8 weeks (2 months). The 3 remaining doses are usually given at 4, 6, and 12 to 15 months. The recommended dosing interval is 4 to 8 weeks. The minimum interval between doses in infants &lt;1 year is 1 month. The minimum interval between the third and fourth dose is 8 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative recommendations</i> Healthy Infants: May consider a total of three 0.5 mL doses with the first dose administered at 2 months, the second dose at 4 months of age and a third dose at 12 months [Canadian National Advisory Committee on Immunizations (NACI) 2016].</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Catch-up Immunization (previously unvaccinated with PCV13):</b> Infants &ge;7 months, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 7 to 11 months: 0.5 mL for a total of 3 doses; first 2 doses at least 4 weeks apart, followed by a third dose after the 1-year birthday (12 to 15 months), separated from the second dose by at least 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 12 to 23 months: 0.5 mL for a total of 2 doses, separated by at least 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Healthy Children 24 to 59 months: 0.5 mL as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 24 to 71 months with an underlying medical condition: 0.5 mL for a total of 2 doses, separated by 8 weeks (CDC/ACIP [Nuorti 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 6 through 17 years: 0.5 mL as a single dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>HSCT (off-label): </b>Children &ge;2 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10010071\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Immunization:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults &ge;65 years: All patients should receive both pneumococcal conjugate vaccine (PCV 13) and pneumococcal polysaccharide vaccine (PPSV23) (ACIP [Kobayashi 2015]; CDC/ACIP [Tomczyk 2014]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pneumococcal vaccine-na&iuml;ve:</i> IM: Administer PCV13 0.5 ml as a single dose, followed by PPSV23 &ge;1 year later (minimum interval of 8 weeks for certain high-risk groups)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Previously received pneumococcal polysaccharide vaccine (PPSV23):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Received at age &lt;65 years: IM: Administer PCV13 0.5 mL as a single dose &ge;1 year after the last dose of PPSV23, followed by PPSV23 at least &ge;1 year later (minimum interval of 8 weeks for certain high-risk groups) and at least  5 years after the last dose of PPSV23</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Received at age &ge;65 years: IM: Administer PCV13 0.5 mL as a single dose &ge;1 year after the last dose of PPSV23; no additional doses of PPSV23 are needed for routine vaccination</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Previously received PCV13:</i>  No additional PCV13 doses are needed</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22448420\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22448421\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10010079\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, suspension:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prevnar 13: 2 mcg of each capsular saccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and 4 mcg of serotype 6B [bound to diphtheria CRM<sub>197</sub> protein ~34 mcg] per 0.5 mL (0.5 mL) [contains aluminum, polysorbate 80, and yeast] </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10010044\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734133\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">In the US, the appropriate CDC-approved Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/pcv13.html&amp;token=xwxQ+ZRVb2+nG9UKFLMZ7LtLZFQMmAYOyw5k18wqcEg4S17o1R1tvh+Q7xbsfGFk4u+B02kMqvZsRO+kCFA7bK8AtSQsFLDSFqHlsS1NKKs=&amp;TOPIC_ID=9906\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/pcv13.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10010076\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM: Shake well prior to use. Do not use if a homogenous white suspension does not form. Administer IM (deltoid muscle for toddlers, young children, and adults or lateral midthigh in infants). Do not inject IV or SubQ; avoid intradermal route. Concurrent administration of PCV13 and PPV23 has not been studied and is not recommended (CDC/ACIP [Nuorti 2010]). Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10010055\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumococcal disease prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Active immunization of infants &ge;6 weeks of age, children, adolescents, and adults for prevention of invasive disease caused by <i>Streptococcus pneumoniae </i>serotypes contained in the vaccine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Active immunization of infants &ge;6 weeks of age and children &lt;6 years of age for the prevention of otitis media caused by <i>S. pneumoniae </i>serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Active immunization of adolescents &ge;18 years of age and adults for the prevention of pneumonia caused by<i> S. pneumoniae</i> serotypes contained in the vaccine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for the following (ACIP [Kobayashi 2015]; CDC/ACIP [Nuorti 2010]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>All infants and children age 2 to 59 months</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Children 60 to 71 months with underlying medical conditions including:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunocompetent children with chronic heart disease (particularly cyanotic congenital heart disease and heart failure), chronic lung disease (including asthma if treated with high dose corticosteroids), diabetes, cerebrospinal fluid leaks, or cochlear implants</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children with functional or anatomic asplenia, including sickle cell disease or other hemoglobinopathies, congenital or acquired asplenia, or splenic dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children with immunocompromising conditions including congenital immunodeficiency (includes B or T cell deficiency, compliment deficiencies and phagocytic disorders; excludes chronic granulomatous disease), HIV infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancies, solid organ transplant, or other diseases requiring immunosuppressive drugs (including long term systemic corticosteroids and radiation therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Children &ge;6 years of age and Adolescents &le;18 years of age (CDC/ACIP, 62[25] 2013), and Adults &ge;19 years (CDC/ACIP, 61[40] 2012):</b> The ACIP also recommends routine vaccination for persons with the following underlying medical conditions:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunocompetent persons with cerebrospinal fluid leaks or cochlear implants</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Persons with functional or anatomic asplenia, including sickle cell disease or other hemoglobinopathies, congenital or acquired asplenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Persons with immunocompromising conditions including congenital or acquired immunodeficiency (includes B or T cell deficiency, compliment deficiencies and phagocytic disorders; excludes chronic granulomatous disease), HIV infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancies, solid organ transplant, multiple myeloma, or other diseases requiring immunosuppressive drugs (including long term systemic corticosteroids and radiation therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>All adults &ge;65 years of age (CDC/ACIP [Tomczyk 2014])</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10010021\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pneumococcal 13-Valent Conjugate Vaccine (Prevnar 13, PCV13) may be confused with Pneumococcal 23-Valent Polysaccharide Vaccine (Pneumovax 23)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">PCV13 (pneumococcal 13-valent conjugate vaccine) may be confused with PPSV23 (pneumococcal 23-valent polysaccharide vaccine)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">PCV (pneumococcal conjugate vaccine; PCV13 is the correct abbreviation) may be confused with MCV (meningococcal ACYW conjugate vaccine, MCV4 is the correct abbreviation)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">PCV (pneumococcal conjugate vaccine; PCV13 is the correct abbreviation) may be confused with PPD (purified protein derivative tuberculin test)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10010061\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills (adults), drowsiness, fatigue (adults), headache (adults), insomnia, irritability (infants and children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (adults: &gt;10%; children and infants: &gt;1%; including urticaria-like rash)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Decreased appetite</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Erythema at injection site, pain at injection site (adults), swelling at injection site, tenderness at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (adults), decreased range of motion (arm), myalgia (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactic shock, anaphylactoid reaction, anaphylaxis, angioedema, apnea, injection site inflammation (dermatitis), injection-site pruritus, crying (abnormal), cyanosis, erythema multiforme, febrile seizures, hypersensitivity reaction (bronchospasm, dyspnea, facial edema), hypotonia, lymphadenopathy (injection site), pallor, seizure, urticaria at injection site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10010058\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Severe allergic reaction (eg, anaphylaxis) to pneumococcal vaccine, any component of the formulation, or any diphtheria toxoid-containing vaccine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10010059\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asplenia: Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in children &ge;24 months of age with asplenia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic illness: Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in children &ge;24 months of age with chronic illness (CDC/ACIP [Nuorti 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV: Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in children &ge;24 months with HIV infection (CDC/ACIP [Nuorti 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pneumococcal infections: Not to be used to treat pneumococcal infections or to provide immunity against diphtheria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sickle cell disease: Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in children &ge;24 months with sickle cell disease (CDC/ACIP [Nuorti 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pneumococcal polysaccharide vaccine (PPSV23): Receipt of PPSV23 within 1 year prior to pneumococcal conjugate vaccine (PCV13) diminishes response to PCV13 when compared to response in PPSV23 na&iuml;ve individuals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy including high-dose corticosteroids); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines (ACIP [Kroger 2017]; IDSA [Rubin 2014]). Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in children &ge;24 months who are immunocompromised (CDC/ACIP [Nuorti 2010]). Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Antibody responses were lower in older adults &gt;65 years compared to adults 50 to 59 years.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Premature infants: Antibody responses were lower in preterm infants (&lt;37 weeks gestational age) compared to term infants (&ge;37 weeks gestational age). Apnea following IM vaccination has been observed in some preterm infants; consider clinical status implications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP Recommended Immunization Schedule (CDC/ACIP [Kim 2017]; CDC/ACIP [Robinson 2017]). Specific recommendations for use of this vaccine in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions are available from the IDSA (Rubin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299890\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10073253\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9906&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Influenza Virus Vaccine (Inactivated): May diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent). Pneumococcal Conjugate Vaccine (13-Valent) may diminish the therapeutic effect of Influenza Virus Vaccine (Inactivated).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meningococcal (Groups A / C / Y and W-135) Diphtheria Conjugate Vaccine: May diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent). Management: It is recommended to administer PCV13 at least 4 weeks prior to the administration of MenACYW-D vaccine in persons with anatomic asplenia or functional asplenia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pneumococcal Polysaccharide Vaccine (23-Valent): May diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent). Management: It is recommended to administer PCV13 prior to administration of PPSV23. The recommended interval between vaccine administrations differs by patient age and comorbidities. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10010057\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not shown adverse fetal effects. Inactivated vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11566484\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if this vaccine is excreted into breast milk. The manufacturer recommends that caution be exercised when administering this vaccine to breastfeeding women. Administration does not affect the safety of breastfeeding for the mother or the infant. Breastfeeding infants should be vaccinated according to the recommended schedules (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28625255\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10010066\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Promotes active immunization against invasive disease caused by <i>S. pneumoniae</i> capsular serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, all which are individually conjugated to CRM197 protein</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390245\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Prevenar 13 (AE, AR, AT, AU, BB, BE, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, ET, FR, GB, GT, HK, HN, HR, ID, IE, IL, IS, JP, KR, KW, LB, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PH, PL, PT, QA, RO, SA, SE, SG, SI, SK, SV, TH, TW, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23),&rdquo; <i>MMWR Morb Mortal Wkly Rep</i>, 2010, 59(34):1102-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/20814406/pubmed\" target=\"_blank\" id=\"20814406\">20814406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Morb Mortal Wkly Rep</i>. 2013;62(25):521-524.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/23803961/pubmed\" target=\"_blank\" id=\"23803961\">23803961</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Morb Mortal Wkly Rep</i>. 2012;61(40):816-819.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/23051612/pubmed\" target=\"_blank\" id=\"23051612\">23051612</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, et al.; Advisory Committee on Immunization Practices (ACIP), ACIP Adult Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older&mdash;United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017; 66(5):136-138. doi: 10.15585/mmwr.mm6605e2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Morb Mortal Wkly Rep</i>. 2015;64(34):944-947.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/26334788/pubmed\" target=\"_blank\" id=\"26334788\">26334788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Advisory Committee on Immunizations. Pneumococcal vaccine. Canadian immunization guide, 2012-2014. Available at: http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-pneu-eng.php#ru. Accessed August 31, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Center for Immunization and Respiratory Diseases (NCIRD). General recommendations on immunization&mdash;recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in <i>MMWR Recomm Rep</i>. 2011;60:993]. <i>MMWR Recomm Rep</i>. 2011;60(2):1-64. 4GODalways<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/21293327/pubmed\" target=\"_blank\" id=\"21293327\">21293327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children: use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2010;59(RR-11):1-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/21150868/pubmed\" target=\"_blank\" id=\"21150868\">21150868</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prevnar 13 (pneumococcal conjugate vaccine [13-valent]) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prevnar 13 (pneumococcal conjugate vaccine [13-valent]) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. <i>Lancet</i>. 2009;374(9698):1339-1350.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reefhuis J, Honein MA, Whitney CG, et al, &ldquo;Risk of Bacterial Meningitis in Children With Cochlear Implants,&rdquo; <i>N Engl J Med</i>, 2003, 349:435-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/12890842/pubmed\" target=\"_blank\" id=\"12890842\">12890842</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson CL, Romero JR, Kempe A, et al.; Advisory Committee on Immunization Practices (ACIP), ACIP Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedules for children and adolescents aged 18 years or younger&mdash;United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):134-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/28182607/pubmed\" target=\"_blank\" id=\"28182607\">28182607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomczyk S, Bennett NM, Stoecker C, et al; Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged &ge;65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Morb Mortal Wkly Rep</i>. 2014;63(37):822-825.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pneumococcal-conjugate-vaccine-13-valent-drug-information/abstract-text/25233284/pubmed\" target=\"_blank\" id=\"25233284\">25233284</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9906 Version 129.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9926715\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F11575096\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F10010046\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F10010070\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F10010068\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F10010071\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22448420\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22448421\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F10010079\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F10010044\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734133\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10010076\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10010055\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F10010021\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F10010061\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F10010058\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F10010059\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299890\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F10073253\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10010057\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F11566484\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F28625255\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F10010066\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390245\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9906|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pneumococcal-conjugate-vaccine-13-valent-patient-drug-information\" class=\"drug drug_patient\">Pneumococcal conjugate vaccine (13-valent): Patient drug information</a></li><li><a href=\"topic.htm?path=pneumococcal-conjugate-vaccine-13-valent-pediatric-drug-information\" class=\"drug drug_pediatric\">Pneumococcal conjugate vaccine (13-valent): Pediatric drug information \t</a></li></ul></div></div>","javascript":null}